Iron oxide nanoparticle agglomeration influences dose rates and modulates oxidative stress-mediated dose-response profiles in vitro

Nanotoxicology

Volumn 8, Issue 6, 2014, Pages 663-675

  Sharma, Gaurav ^a,b   Kodali, Vamsi ^b   Gaffrey, Matthew ^b   Wang, Wei ^a,c   Minard, Kevin R ^a,b   Karin, Norman J ^a,b   Teeguarden, Justin G ^a,b   Thrall, Brian D ^a,b  

^a BATTELLE MEMORIAL INSTITUTE   (United States)

^b PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^c OAK RIDGE NATIONAL LABORATORY   (United States)

Author keywords

Agglomeration; Dosimetry modelling; Gene expression; Iron oxide nanoparticles; Nanotoxicology; Oxidative stress

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; THIOREDOXIN REDUCTASE 1; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ARTICLE; BIOCOMPATIBILITY; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DOSE RESPONSE; DOSIMETRY; EPITHELIUM CELL; GENE EXPRESSION; HYDRODYNAMICS; IN VITRO STUDY; LUNG ALVEOLUS EPITHELIUM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PARTICLE SIZE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SURFACE PROPERTY; ZETA POTENTIAL;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MAGNETITE NANOPARTICLES; MICE; OXIDATIVE STRESS; PARTICLE SIZE; SERUM;

EID: 84890368013     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.3109/17435390.2013.822115     Document Type: Article

References (53)

1. Albanese A, Chan WC. 2011. Effect of gold nanoparticle aggregation on cell uptake and toxicity. ACS Nano 5:5478-5489
2. Albanese A, Tang PS, Chan WC. 2012. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14:1-16
3. Apopa PL, Qian Y, Shao R, Guo NL, Schwegler-Berry D, Pacurari M, et al. 2009. Iron oxide nanoparticles induce human microvascular endothelial cell permeability through reactive oxygen species production and microtubule remodeling. Part Fibre Toxicol 6:1
4. Bihari P, Vippola M, Schultes S, Praetner M, Khandoga AG, Reichel CA, et al. 2008. Optimized dispersion of nanoparticles for biological in vitro and in vivo studies. Part Fibre Toxicol 5:14
5. Brunner TJ, Wick P, Manser P, Spohn P, Grass RN, Limbach LK, et al. 2006. In vitro cytotoxicity of oxide nanoparticles: Comparison to asbestos, silica, and the effect of particle solubility. Environ Sci Technol 40:4374-4381
6. Cohen J, Deloid G, Pyrgiotakis G, Demokritou P. 2012. Interactions of engineered nanomaterials in physiological media and implications for in vitro dosimetry. Nanotoxicology 7:417-431
7. Derjaguin B, Landau L. 1993. Theory of the stability of strongly charged lyophobic sols and of the adhesion of strongly charged particles in solutions of electrolytes. Prog Surf Sci 43:30-59
8. Drescher D, Orts-Gil G, Laube G, Natte K, Veh RW, Osterle W, et al. 2011. Toxicity of amorphous silica nanoparticles on eukaryotic cell model is determined by particle agglomeration and serum protein adsorption effects. Anal Bioanal Chem 400:1367-1373
9. Ferguson RM, Minard KR, Khandhar AP, Krishnan KM. 2011. Optimizing magnetite nanoparticles for mass sensitivity in magnetic particle imaging. Med Phys 38:1619-1626
10. Gosens I, Post JA, De LA Fonteyne LJ, Jansen EH, Geus JW, Cassee FR, et al. 2010. Impact of agglomeration state of nanoand submicron sized gold particles on pulmonary inflammation. Part Fibre Toxicol 7:37
11. Gualtieri M, Skuland T, Iversen TG, Lag M, Schwarze P, Bilanicova D, et al. 2011. Importance of agglomeration state and exposure conditions for uptake and pro-inflammatory responses to amorphous silica nanoparticles in bronchial epithelial cells. Nanotoxicology 6:700-712
12. Hinderliter PM, Minard KR, Orr G, Chrisler WB, Thrall BD, Pounds JG, et al. 2010. ISDD: A computational model of particle sedimentation, diffusion and target cell dosimetry for in vitro toxicity studies. Part Fibre Toxicol 7:36
13. Hinderliter PM, Price PS, Bartels MJ, Timchalk C, Poet TS. 2011. Development of a source-To-outcome model for dietary exposures to insecticide residues: An example using chlorpyrifos. Regul Toxicol Pharmacol 61:82-92
14. Huang HC, Barua S, Sharma G, Dey SK, Rege K. 2011. Inorganic nanoparticles for cancer imaging and therapy. J Control Release 155:344-357
15. Huber DL. 2005. Synthesis, properties, and applications of iron nanoparticles. Small 1:482-501
16. Karlsson HL, Gustafsson J, Cronholm P, Moller L. 2009. Size-dependent toxicity of metal oxide particles-A comparison between nanoand micrometer size. Toxicol Lett 188:112-118
17. Kato T, Yashiro T, Murata Y, Herbert DC, Oshikawa K, Bando M, et al. 2003. Evidence that exogenous substances can be phagocytized by alveolar epithelial cells and transported into blood capillaries. Cell Tissue Res 311:47-51
18. Kittler S, Greulich C, Gebauer JS, Diendorf J, Treuel L, Ruiz L, et al. 2010. The influence of proteins on the dispersability and cell-biological activity of silver nanoparticles. J Mater Chem 20:512-518
19. Lesniak A, Campbell A, Monopoli MP, Lynch I, Salvati A, Dawson KA. 2010. Serum heat inactivation affects protein corona composition and nanoparticle uptake. Biomaterials 31:9511-9518
20. Li JJ, Muralikrishnan S, Ng CT, Yung LY, Bay BH. 2010. Nanoparticle-induced pulmonary toxicity. Exp Biol Med 235:1025-1033
21. Limbach LK, Li Y, Grass RN, Brunner TJ, Hintermann MA, Muller M, et al. 2005. Oxide nanoparticle uptake in human lung fibroblasts: Effects of particle size, agglomeration, and diffusion at low concentrations. Environ Sci Technol 39:9370-9376
22. Lu AH, Salabas EL, Schuth F. 2007. Magnetic nanoparticles: Synthesis, protection, functionalization, and application. Angew Chem Int Ed Engl 46:1222-1244
23. Mahl D, Greulich C, Meyer-Zaika W, Koller M, Epple M. 2010. Gold nanoparticles: Dispersability in biological media and cell-biological effect. J Mater Chem 20:6176-6181
24. Mahmoudi M, Hofmann H, Rothen-Rutishauser B, Petri-Fink A. 2012. Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. Chem Rev 112:2323-2338
25. Mahmoudi M, Laurent S, Shokrgozar MA, Hosseinkhani M. 2011. Toxicity evaluations of superparamagnetic iron oxide nanoparticles: Cell "vision" versus physicochemical properties of nanoparticles. ACS Nano 5:7263-7276
26. Mahmoudi M, Simchi A, Imani M, Milani AS, Stroeve P. 2009. An in vitro study of bare and poly(ethylene glycol)-co-fumarate-coated superparamagnetic iron oxide nanoparticles: A new toxicity identification procedure. Nanotechnology 20:225104
27. Maiorano G, Sabella S, Sorce B, Brunetti V, Malvindi MA, Cingolani R, et al. 2010. Effects of cell culture media on the dynamic formation of protein-nanoparticle complexes and influence on the cellular response. ACS Nano 4:7481-7491
28. Maynard AD, Aitken RJ, Butz T, Colvin V, Donaldson K, Oberdorster G, et al. 2006. Safe handling of nanotechnology. Nature 444:267-269
29. Minard KR, Littke MH, Wang W, Xiong Y, Teeguarden JG, Thrall BD. 2012. Magnetic particle detection (MPD) for in-vitro dosimetry. Biosens Bioelectron 43:88-93
30. Murdock RC, Braydich-Stolle L, Schrand AM, Schlager JJ, Hussain SM. 2008. Characterization of nanomaterial dispersion in solution prior to in vitro exposure using dynamic light scattering technique. Toxicol Sci 101:239-253
31. Oberdorster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, et al. 2005. Principles for characterizing the potential human health effects from exposure to nanomaterials: Elements of a screening strategy. Part Fibre Toxicol 2:8
32. Okuda-Shimazaki J, Takaku S, Kanehira K, Sonezaki S, Taniguchi A. 2010. Effects of titanium dioxide nanoparticle aggregate size on gene expression. Int J Mol Sci 11:2383-2392
33. Ovrevik J, Refsnes M, Namork E, Becher R, Sandnes D, Schwarze PE, et al. 2006. Mechanisms of silica-induced IL-8 release from A549 cells: Initial kinase-Activation does not require EGFR activation or particle uptake. Toxicology 227:105-116
34. Park EJ, Choi J, Park YK, Park K. 2008. Oxidative stress induced by cerium oxide nanoparticles in cultured BEAS-2B cells. Toxicology 245:90-100
35. Rezwan K, Meier LP, Rezwan M, Voros J, Textor M, Gauckler LJ. 2004. Bovine serum albumin adsorption onto colloidal Al2O3 particles: A new model based on zeta potential and UV-vis measurements. Langmuir 20:10055-10061
36. Sager TM, Porter DW, Robinson VA, Lindsley WG, Schwegler-Berry DE, Castranova V. 2007. Improved method to disperse nanoparticles for in vitro and in vivo investigation of toxicity. Nanotoxicology 1:118-119
37. Schwertmann U. 1991. Solubility and dissolution of iron oxides. Plant Soil 130:1-25
38. Singh N, Jenkins GJ, Asadi R, Doak SH. 2010. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev 1:10
39. Sterling MC JR, Bonner JS, Ernest AN, Page CA, Autenrieth RL. 2005. Application of fractal flocculation and vertical transport model to aquatic sol-sediment systems. Water Res 39:1818-1830
40. Stringer B, Imrich A, Kobzik L. 1996. Lung epithelial cell (A549) interaction with unopsonized environmental particulates: Quantitation of particle-specific binding and IL-8 production. Exp Lung Res 22:495-508
41. Stroh A, Zimmer C, Gutzeit C, Jakstadt M, Marschinke F, Jung T, et al. 2004. Iron oxide particles for molecular magnetic resonance imaging cause transient oxidative stress in rat macrophages. Free Radic Biol Med 36:976-984
42. Teeguarden J, Gupta A, Escobar P, Jackson M. 2008. Toxicology steps up to nanotechnology safety. RD Magazine 50:28-29
43. Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. 2007. Particokinetics in vitro: Dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol Sci 95:300-312
44. Veranth JM, Kaser EG, Veranth MM, Koch M, Yost GS. 2007. Cytokine responses of human lung cells (BEAS-2B) treated with micron-sized and nanoparticles of metal oxides compared to soil dusts. Part Fibre Toxicol 4:2
45. Voinov MA, Sosa Pagan JO, Morrison E, Smirnova TI, Smirnov AI. 2011. Surface-mediated production of hydroxyl radicals as a mechanism of iron oxide nanoparticle biotoxicity. J Am Chem Soc 133:35-41
46. Warheit DB. 2001. Inhaled amorphous silica particulates: What do we know about their toxicological profiles? J Environ Pathol Toxicol Oncol 20(Suppl 1):133-141
47. Weaver TE, Whitsett JA. 1991. Function and regulation of expression of pulmonary surfactant-Associated proteins. Biochem J 273(Pt 2):249-264
48. Wells MA, Abid A, Kennedy IM, Barakat AI. 2011. Serum proteins prevent aggregation of Fe2O3 and ZnO nanoparticles. Nanotoxicology 6:837-846
49. Wohlleben W. 2012. Validity range of centrifuges for the regulation of nanomaterials: From classification to as-Tested coronas. J Nanopart Res 14:1300
50. Xia T, Kovochich M, Brant J, Hotze M, Sempf J, Oberley T, et al. 2006. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett 6:1794-1807
51. Ying E, Hwang HM. 2010. In vitro evaluation of the cytotoxicity of iron oxide nanoparticles with different coatings and different sizes in A3 human T lymphocytes. Sci Total Environ 408:4475-4481
52. Zhang H, Ji Z, Xia T, Meng H, Low-Kam C, Liu R, et al. 2012. Use of metal oxide nanoparticle band gap to develop a predictive paradigm for oxidative stress and acute pulmonary inflammation. ACS Nano 6:4349-4368
53. Zook JM, Maccuspie RI, Locascio LE, Halter MD, Elliott JT. 2011. Stable nanoparticle aggregates/agglomerates of different sizes and the effect of their size on hemolytic cytotoxicity. Nanotoxicology 5:517-530